HEPHA440
/ HEPHAISTOS-Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
HEPHA440, an innate immune modulator displaying potent antitumor activity across multiple myeloid-rich immunosuppressive tumor models with a favorable preclinical safety profile
(SITC 2026)
- No abstract available
Preclinical • Oncology
1 to 1
Of
1
Go to page
1